Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology Group

11 Jun 2024

Abstract excerpt

Juvenile myelomonocytic leukemia (JMML) is a hematologic malignancy of young children caused by mutations that increase Ras signaling output. Hematopoietic stem cell transplantation (HSCT) is a potentially curative treatment, but patients with relapsed or refractory (advanced) disease have dismal outcomes. This phase II trial evaluated the safety and efficacy of trametinib, an oral MEK1/2 inhibitor, in patients...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Acute Myeloid Leukemia Research
Share to Chronic Lymphocytic Leukemia Research
Share to PI3K/AKT/mTOR signaling in cancer

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Source

Identifiers

PMID: 38867349
DOI: 10.1158/2159-8290.cd-23-1376

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 23 Oct 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Efficacy of the Allosteric MEK Inhibitor Trametinib in Relapsed and Refractory Juvenile Myelomonocytic Leukemia: a Report from the Children’s Oncology GroupPMID 38867349Read ↗

Bedside to bench in juvenile myelomonocytic leukemia: insights into leukemogenesis from a rare pediatric leukemia.Semantic proximity Read ↗

Juvenile myelomonocytic leukemia: who’s the driver at the wheel?Semantic proximity Read ↗

Targeted therapy in juvenile myelomonocytic leukemia: Where are we now?Semantic proximity Read ↗

Current Treatment of Juvenile Myelomonocytic LeukemiaSemantic proximity Read ↗

Novel approaches to diagnosis and treatment of Juvenile Myelomonocytic Leukemia.Semantic proximity Read ↗

Potential clinical use of azacitidine and MEK inhibitor combination therapy in PTPN11-mutated juvenile myelomonocytic leukemia.Semantic proximity Read ↗

Mutation-specific signaling profiles and kinase inhibitor sensitivities of juvenile myelomonocytic leukemia revealed by induced pluripotent stem cells.Semantic proximity Read ↗

Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network.Semantic proximity Read ↗

Characteristics of RAS pathway mutations in juvenile myelomonocytic leukaemia: a single-institution study from Korea.Semantic proximity Read ↗

Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.Semantic proximity Read ↗

Recent advances in the pathogenesis and management of juvenile myelomonocytic leukaemia.Semantic proximity Read ↗

Despite mutation acquisition in hematopoietic stem cells, JMML-propagating cells are not always restricted to this compartment.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.